Company Quick10K Filing
Sage Therapeutics
Closing Price ($) Shares Out (MM) Market Cap ($MM)
$0.00 51 $8,814
10-K 2020-02-27 Annual: 2019-12-31
10-Q 2019-11-12 Quarter: 2019-09-30
10-Q 2019-08-06 Quarter: 2019-06-30
10-Q 2019-05-02 Quarter: 2019-03-31
10-K 2019-02-19 Annual: 2018-12-31
10-Q 2018-11-06 Quarter: 2018-09-30
10-Q 2018-08-07 Quarter: 2018-06-30
10-Q 2018-05-03 Quarter: 2018-03-31
10-K 2018-02-22 Annual: 2017-12-31
10-Q 2017-11-02 Quarter: 2017-09-30
10-Q 2017-08-03 Quarter: 2017-06-30
10-Q 2017-05-10 Quarter: 2017-03-31
10-K 2017-02-24 Annual: 2016-12-31
10-Q 2016-11-03 Quarter: 2016-09-30
10-Q 2016-08-09 Quarter: 2016-06-30
10-Q 2016-05-06 Quarter: 2016-03-31
10-K 2016-02-29 Annual: 2015-12-31
10-Q 2015-11-06 Quarter: 2015-09-30
10-Q 2015-08-12 Quarter: 2015-06-30
10-Q 2015-05-15 Quarter: 2015-03-31
10-K 2015-03-06 Annual: 2014-12-31
10-Q 2014-11-13 Quarter: 2014-09-30
10-Q 2014-08-14 Quarter: 2014-06-30
8-K 2020-03-18 Other Events, Exhibits
8-K 2020-02-27 Earnings, Exhibits
8-K 2019-12-05 Other Events, Exhibits
8-K 2019-11-12 Earnings, Exhibits
8-K 2019-08-06 Earnings, Exhibits
8-K 2019-07-24 Other Events, Exhibits
8-K 2019-06-14 Other Events, Exhibits
8-K 2019-06-05 Shareholder Vote
8-K 2019-05-02 Earnings, Exhibits
8-K 2019-03-19 Other Events, Exhibits
8-K 2019-02-27 Other Events, Exhibits
8-K 2019-02-25 Enter Agreement, Other Events, Exhibits
8-K 2019-02-19 Earnings, Exhibits
8-K 2019-01-22 Officers, Other Events, Exhibits
8-K 2019-01-07 Regulation FD, Other Events, Exhibits
8-K 2018-11-20 Other Events, Exhibits
8-K 2018-11-06 Earnings, Exhibits
8-K 2018-11-02 Other Events, Exhibits
8-K 2018-08-07 Earnings, Exhibits
8-K 2018-06-13 Other Events, Exhibits
8-K 2018-06-12 Other Events, Exhibits
8-K 2018-06-06 Shareholder Vote
8-K 2018-05-30 Other Events, Exhibits
8-K 2018-05-03 Earnings, Exhibits
8-K 2018-02-22 Earnings, Exhibits
8-K 2018-02-13 Other Events
8-K 2018-02-07 Other Events, Exhibits
8-K 2018-02-07 Enter Agreement, Other Events, Exhibits
8-K 2018-02-07 Regulation FD
8-K 2018-01-31 Other Events, Exhibits
8-K 2018-01-08 Other Events, Exhibits

Sage Therapeutics Financials

SAGE Metrics, Comps, Filings

Annual | Quarterly

Business

We are a clinical-stage biopharmaceutical company committed to developing and commercializing novel medicines to treat life-altering central nervous system, or CNS, disorders, where there are no approved therapies or existing therapies are inadequate. We have a portfolio of product candidates with a current focus on modulating two critical CNS receptor systems, GABA and NMDA. The GABA receptor family, which is recognized as the major inhibitory neurotransmitter in the CNS, mediates downstream neurologic and bodily function via activation of GABAA receptors. The NMDA-type receptors of the glutamate receptor system are a major excitatory receptor system in the CNS. Dysfunction in these systems is implicated in a broad range of CNS disorders. We are targeting CNS indications where patient populations are easily identified, clinical endpoints are well-defined, and development pathways are feasible.

Our lead product candidate is ZULRESSO™ (brexanolone) injection, a proprietary intravenous, or IV, formulation of brexanolone for which we have filed a new drug application, or NDA, with the United States Food and Drug Administration, or the FDA, seeking approval to market and sell the product in the treatment of postpartum depression, or PPD. Brexanolone is chemically identical to allopregnanolone, a naturally occurring neuroactive steroid that acts as a positive allosteric modulator of GABAA receptors. PPD is a common biological complication of childbirth, and is characterized by significant depressive symptoms that typically commence during the third trimester of pregnancy or in the months following childbirth. Our NDA for ZULRESSO is currently under FDA review. On November 2, 2018, the Psychopharmacologic Drugs Advisory Committee, or PDAC, and Drug Safety and Risk Management, or DSaRM, Advisory Committee of the FDA jointly voted, by a vote of 17 to 1, that our data support a positive benefit/risk profile for ZULRESSO in the treatment of PPD when administered by qualified staff in a healthcare facility certified under a Risk Evaluation and Mitigation Strategies, or REMS, program. In November 2018, the FDA extended the previously disclosed December 19, 2018 Prescription Drug User Fee Act, or PDUFA, target date for a decision on the NDA for ZULRESSO by a period of three months to March 19, 2019. The launch of ZULRESSO in the U.S., if approved, will follow anticipated scheduling of brexanolone as a controlled substance by the Drug Enforcement Administration, or DEA, which we expect to be completed 90 days after FDA approval. We anticipate that ZULRESSO, if approved, will launch in the U.S. in June 2019.

insomnia, known as the Rainforest Study. We expect to report top-line results from the Rainforest Study and the Shoreline Study in 2020.


Valuation ($BB)

Market Cap, Enterprise Value

Balance Sheet ($BB)

Assets, Stockholders' Equity

Income Statement ($BB Annual)

Revenue, Gross Profit, Net Income

Cash Flow ($BB Annual)

Operating, Investing, Financing

Comps ($MM TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
Elanco Animal Health (ELAN) 9,964 52% 30.6 1% 8,824 3,336 3,083 1,611 94 393 12,004
Mylan (MYL) 10,768 34% 12.5 -0% 31,054 19,590 8,309 2,810 -4 1,882 23,458
Teva (TEVA) 7,142 43% -10.6 -7% 57,246 42,322 17,455 7,550 -3,961 -2,814 29,713
Sarepta Therapeutics (SRPT) 5,588 0% -7.9 -36% 1,702 707 365 0 -620 -576 4,529
Ionis Pharmaceuticals (IONS) 8,784 76% 17.4 15% 2,895 1,397 821 626 436 491 8,536
Sage Therapeutics (SAGE) 7,414 82% -10.7 -56% 1,204 123 5 4 -670 -670 7,152
Bausch (BHC) 7,760 0% 25.3 -1% 31,667 29,107 8,498 0 -266 1,216 30,774
Alnylam Pharmaceuticals (ALNY) 8,913 80% -9.7 -32% 2,542 935 169 135 -821 -820 7,987
Catalent (CTLT) 7,405 32% 23.8 2% 6,120 3,864 2,631 834 152 421 10,021
Jazz Pharmaceuticals (JAZZ) 7,549 21% 11.2 11% 5,528 2,473 2,056 441 609 762 8,530
Dr Reddys Laboratories (RDY) 6,726 0% 225,427 85,230 0 0 0 0 6,714
Perrigo (PRGO) 7,421 37% 17.9 2% 11,311 5,552 4,710 1,735 247 580 10,388
Amarinuk (AMRN) 5,417 61% -75.7 -7% 867 271 364 221 -63 -63 4,799
Nektar Therapeutics (NKTR) 3,147 81% -7.6 -20% 2,088 600 121 98 -425 -401 3,065
Array Biopharma (ARRY) 5,260 92% -43.6 -22% 567 265 240 221 -126 -114 4,960
Galapagos (GLPG) 5,015 0% 1,439 225 0 0 0 0 5,015
Loxo Oncology (LOXO) 4,868 0% 697.4 1% 659 280 124 0 7 7 4,732
Blueprint Medicines (BPMC) 3,599 0% -8.5 -49% 738 222 16 0 -362 -354 3,005
Horizon Pharma (HZNP) 5,349 71% 26.5 2% 3,721 2,166 1,292 915 68 222 5,880
Taro Pharmaceutical Industries (TARO) 4,157 0% 2,135 224 0 0 0 0 3,589

Balance Sheet ($MM)2014-12-312014-12-312015-12-312016-12-312017-12-312018-12-31
Cash128128187169306193
Accounts Receivable
Inventory
PP&E000146
Assets130130189405530953
Accounts Payable22513934
Long-Term Debt
Liabilities8815365490
Stockholders' Equity122122174369475863
Income Statement ($MM)2014-12-312014-12-312015-12-312016-12-312017-12-312018-12-31
Revenue90
Cost of Revenue
Gross Profit
R&D242469121210282
SG&A1010253963201
Tax00000
Net Income-34-34-94-159-270-373
Cash Flow ($MM)2014-12-312014-12-312015-12-312016-12-312017-12-312018-12-31
Cash Operating-27-27-71-119-219-261
Cash Investing-0-0-0-23115-512
Cash Financing147147130331342659